Mathias Svahn

Mathias Svahn

Company: Next Cell Pharma

Job title: CEO


The Development of Allogeneic Mesenchymal Stem Cell Therapies for Type 1 Diabetes 9:45 am

Preserve endogenous insulin production in adult patients diagnosed with type I diabetes by immunomodulatory allogeneic mesenchymal stromal cells Redundant source of primary hMSC for scalable manufacturing Selection algorithm developed to select optimal cells based on multiple functional assays and mechanisms of action Drug product currently in two clinical trialsRead more

day: Day Two

© Copyright 2018 Hanson Wade | Design and site by Event Engine | Hanson Wade Limited is registered in England & Wales, number 06752216.
Registered Office: Suite A, 6 Honduras Street, London EC1Y 0TH.